was performed using 32P radio-end-labeled primers and the PerkinElmer GeneAmp kit (Perkin-Elmer-Cetus, Emeryville, CA). Quantitation of PCR amplified products was achieved by amplification (25 cycles) of known amounts of plasmid DNA (diluted into I pg cellular DNA), normal cellular DNA, or RNA from the PA317 virus-producing cell line.
Cell sorting. Live cell sorting was performed using a FACStarP'"' flow cytometer (Becton-Dickinson, Mountain View, CA), as previously described.'
Preparation and reconstitution of SCID-hu mice. SCID-hu mice were constructed by implantation of human fetal liver and thymus pieces under the murine kidney capsule, as previously de~cribed.''.~.~ For reconstitution, animals were irradiated with 200 rads 4 to 6 months postimplantation, and implants directly injected with CD34' cells within 24 hours. Sequential wedge biopsies of thymic implants were obtained at the timepoints indicated as previously described.' 
RESULTS

Transduction
fraction of these progenitor cells is known to constitute hematopoietic stem cells with self-renewing properties. In this study, human CD34' fetal liver progenitor cells were purified from single-cell suspensions of enzymatically disrupted liver by single-step affinity column ~hromatography.'~ This procedure increased the purity of CD34' cells from approximately 17% to 92% to 99%. as assessed by flow cytometry (not shown). The purified CD34' cells were transduced in vitro with a helper virus-free retroviral vector (LNL6) containing the neomycin (G418) resistance gene (neoR)." Because retroviral vectors do not stably reverse transcribe or integrate into nondividing the CD34' cell population was subjected to cytokine-driven expansion and division in media containing interleukins -3 and -6 and stem cell factor. Transduction was accomplished by cocultivation with the PA317 producer cell line in the presence of growth factors, separated by a membrane bamer that is permeable for the virus. About 10% of the cells were transduced, according to analysis by quantitative PCR for the presence of vector sequences (Fig I To determine if the retrovirus-transduced CD34' cells could reconstitute the human thymus and give rise to mature CD4' and CD8' lymphoid cells, the transduced cells were directly injected into Thyniv implants of SCID-hu mice sublethally irradiated previously to deplete the endogenous population of human thymocytes. Sequential biopsies of the implants were obtained from the irradiated reconstituted and irradiated control mice at 4 and 6 weeks postreconstitution to determine the fate of the injected cells. Cells were analyzed by two-color flow cytometry for the presence of CD4 and CD8 antigens.* Five of seven irradiated animals that did not receive transduced CD34' cells showed depleted cell
populations as a result of irradiation (Fig IB) . Two of seven control animals showed a normal distribution, presumably because of failure to completely clear the endogenous stem cells. In contrast, IO of I O irradiated animals injected with 50,000 or more transduced CD34' cells had normal distribution profiles of CD4/CD8 double-positive. CD4'/CD8-and CD4-/CD8' human thymocytes, indicating successful reconstitution of the T-lymphoid lineage.
Presence qf neoR vector sequences in reconstituted mice.
To further establish that thymocytes which developed after reconstitution were of donor origin. samples obtained at 4 and 6 weeks postreconstitution were analyzed by quantitative PCR for the presence of transduced neoR vector sequences (Fig IA) . Approximately 3% of the cells contained vector sequences, showing that the transduced gene was retained by these cells. Thus. exogenous transduced precursor cells can repopulate thymic implants while retaining transduced DNA sequences at levels slightly lower than those seen in the input CD34' cells. This may be a consequence of the fact that the transduction efficiency of the total CD34' pool does not reflect the transduction efficiency of the thymocyte precursors selected for growth in vivo. Expression qf neo' RNA in reconstitrcted mice. We determined the expression of neoR in the reconstituted implant. The total thymocyte population obtained at 6 weeks postreconstitution was examined by RT-PCR for the presence of neoR mRNA. Our results showed that neoR was expressed at low but detectable levels (Fig IC) . Levels of mRNA expression in thymocytes were estimated by comparison with that of the PA3 17 virus-producing cell line. and found to be approximately 150-fold lower on a per-infected cell basis. We cannot distinguish by this analysis whether all trans- Number qf CD34' cells required to reconstitrcte SCID-hu mice. We also determined the minimum number of transduced CD34' cells needed to reconstitute the thymic implant by injecting various amounts of cells into the implants of irradiated SCID-hu mice. PCR analysis of cells for neoR obtained at 4 weeks postreconstitution showed that in this system, 5 X IO4 CD34' cells are required to reconstitute a thymic implant with cells containing the transduced vector (Fig 2) . Analysis of the same samples using human Y-chro- Presence of neoR in thymocyte subpopulations. The presence of foreign gene sequences could potentially have deleterious effects on cells undergoing lineage-specific expansion and differentiation. Therefore, we determined if neoR sequences were present in various thymocyte subpopulations as they matured into end-stage cells. Four weeks postreconstitution, biopsy samples were obtained and thymocytes were sorted into immature CD4/CD8 double-positive and mature CD4+/CD8-and CD4-/CD8+ populations, and analyzed by quantitative PCR for neoR sequences (Fig 3) . When normalized for human cell equivalents, approximately 2% of the cells of each thymocyte subpopulation contained the marker, thus directly showing neoR sequences in differentiated T cells and indicating that the presence of the vector was not toxic to thymocyte differentiation.
DISCUSSION
Currently, the only means to test vectors and therapeutic reagents for human lymphoid precursor cell gene therapy is in vitro or through clinical trials. The SCID-hu mouse is the first in vivo system that can be used to supplement clinical testing by allowing more rapid development of gene therapy strategies for human lymphoid cell disorders. In this system, progenitor cells can be transduced in vitro with therapeutic genes and introduced into the human thymic micro-environment to determine the effects on lineage-specific differentiation. Each of the critical steps in gene therapy, including vector transduction, efficiency, stem cell reconstitution, vector expression, and regulation, can be investigated in a relatively rapid, experimentally manipulatable in vivo system that accurately mimics many aspects of human lymphopoiesis. The fate and expression of foreign genes can be monitored at different levels of development, and possible toxic effects of various gene constructs on differentiation steps can be assessed. This model potentially allows testing of gene therapeutic reagents for both genetic and acquired diseases of the T-lymphoid cell lineage.
One immediate application for the SCID-hu model will be to assess effects of gene therapy strategies for acquired immunodeficiency syndrome (AIDS). We and others previously showed that human immunodeficiency virus type 1 (HIV-1) infection of the ThyLiv implant results in depletion of CD4-bearing cell^.^*'^.'^ Thus, this will be an ideal model to investigate gene therapeutic reagents targeted at HIV-1 and AIDS. CD34+ cells could be transduced with various anti-HIV-1 gene therapy vector^,^^^^^ allowed to differentiate into CD4-bearing lymphocytes in SCID-hu mice, and subsequently challenged with HIV-1 to assess protective effects. This system can be used to rapidly develop appropriate vectors, expression systems, and other gene therapy strategies for AIDS.
